In PSMAfore, [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) prolonged radiographic progression-free survival (rPFS) in taxane-naive patients with metastatic castration-resistant prostate cancer (mCRPC), with a favourable safety profile, versus a change in androgen receptor pathway inhibitor (ARPI). We report the final overall survival (OS) analysis and updated safety data.
Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer
Annals of Oncology | | K. Fizazi, K.N. Chi, N.D. Shore, K. Herrmann, J.S. de Bono, D. Castellano, J.M. Piulats, A. Fléchon, X.X. Wei, H. Mahammedi, G. Roubaud, M. Fleming, T. Haas, S. Ghebremariam, T.N. Kreisl, S. Rajagopalan, O. Sartor, M.J. Morris, PSMAfore Investigators
Topics: prostate-cancer, blood-cancer, chemotherapy, clinical-trials, research